| Status: Recommended | ||
Lacosamide (Vimpat®) is recommended as an option for use within NHS Wales as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from 2 years of age to ≤ 15 years of age with epilepsy. |
||
|
||
Medicine details |
||
| Medicine name | lacosamide (Vimpat®) | |
| Formulation | 10 mg/ml syrup; 10 mg/ml solution for infusion; 50 mg, 100 mg, 150 mg, 200 mg film-coated tablets | |
| Reference number | 4698 | |
| Indication | Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from 2 years of age to ≤ 15 years of age with epilepsy |
|
| Company | UCB Pharma Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Licence extension for paediatric use | |
| Status | Recommended | |
| Advice number | 1722 | |
| AWMSG meeting date | 14/09/2022 | |
| Date of issue | 03/10/2022 | |
| Further information This advice incorporates and replaces the AWMSG recommendation for lacosamide (Vimpat®) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from ≥ 4 years of age to ≤ 15 years of age (advice number 0318, originally published March 2018). |
||